Author/Authors :
Gurram R. Madhavan، نويسنده , , Ranjan Chakrabarti، نويسنده , , Reeba K Vikramadithyan، نويسنده , , Rao N.V.S Mamidi، نويسنده , , V Balraju، نويسنده , , B.M Rajesh، نويسنده , , Parimal Misra، نويسنده , , Sunil K.B Kumar، نويسنده , , Braj B Lohray، نويسنده , , Vidya B Lohray، نويسنده , , Ramanujam Rajagopalan، نويسنده ,
Abstract :
A series of pyrimidinone derivatives of thiazolidinediones were synthesized. Their biological activity were evaluated in insulin resistant, hyperglycemic and obese db/db mice. In vitro PPARγ transactivation assay was performed in HEK 293T cells. PMT13 showed the best biological activity in this series. PMT13 (5-[4-[2-[2-ethyl-4-methyl-6-oxo-1,6-dihydro-1-pyrimidinyl]ethoxy]phenylmethyl]thiazolidine-2,4-dione) showed better plasma glucose, triglyceride and insulin-lowering activity in db/db mice than rosiglitazone and pioglitazone. PMT13 showed better PPARγ transactivation than the standard compounds. Pharmacokinetic study in Wistar rats showed good systemic exposure of PMT13. Twenty-eight day oral toxicity study in Wistar rats did not show any treatment-related adverse effects.
